Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11212743 | 0.93 | PPARG (0.46) | PPARGPPARAPTGS2ALDH1A1LPL | |
| SCHEMBL1171484 | 0.89 | CNR1 (0.37) | MAPK1NPC1RAB9APPARGPPARA | |
| SCHEMBL15474810 | 0.84 | CYP2C8 (0.37) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL27680870 | 0.84 | SKP2 (0.39) | SKP2HPGDMAPK1NPC1HTT | |
| SCHEMBL29280364 | 0.84 | SKP2 (0.39) | SKP2HPGDMAPK1NPC1HTT | |
| SCHEMBL5068404 | 0.83 | SKP2 (0.36) | SKP2HPGDMAPK1NPC1HTT | |
| SCHEMBL6184432 | 0.83 | BCL2L2 (0.38) | PPARGPPARAALDH1A1LPLLIPG | |
| SCHEMBL8704610 | 0.83 | SKP2 (0.38) | SKP2HPGDMAPK1NPC1HTT | |
| SCHEMBL15474773 | 0.82 | HTR1A (0.44) | ALDH1A1 | |
| SCHEMBL15474522 | 0.81 | SIGMAR1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009150-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | WEBER OLAF (DE) | 2012-01-12 | — | — | US | claimed |
| US-20110263657-A1 | DIARYL UREAS FOR TREATING HEART FAILURE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-27 | — | — | US | claimed |
| US-20110158942-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | WEBER OLAF | 2011-06-30 | — | — | US | claimed |
| EP-2338488-A1 | Drug combinations with substituted diaryl ureas for the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-06-29 | — | — | EP | claimed |
| EP-2313376-A2 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2011-04-27 | — | — | EP | claimed |
| EP-2293792-A1 | DIARYL UREAS FOR TREATING HEART FAILURE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-16 | — | — | EP | claimed |
| EP-1948176-B1 | DIARYL UREAS FOR TREATING PULMONARY HYPERTENSION | BAYER SCHERING PHARMA AG (DE) | 2011-01-05 | — | — | EP | claimed |
| WO-2009156089-A1 | DIARYL UREAS FOR TREATING HEART FAILURE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-30 | — | — | WO | claimed |
| US-20090306020-A1 | Combination therapy comprising diaryl ureas for treating diseases | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | claimed |
| US-20090227637-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-09-10 | — | — | US | claimed |
| US-20030144278-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20020137774-A1 | Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-09-26 | — | — | US | claimed |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-04-11 | — | — | US | claimed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | claimed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | claimed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | claimed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | claimed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | claimed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | claimed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306020-A1 | Combination therapy comprising diaryl ureas for treating diseases | CDK6, UBA6, CHUK | SKP2 181/4885HPGD 2669/4885MAPK1 222/4885 |
| US-20120009150-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | UBA6, MCM6, UBQLN1 | SKP2 641/4885HPGD 3968/4885MAPK1 3365/4885 |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | SKP2 503/4885HPGD 2652/4885MAPK1 447/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | SKP2 777/4885HPGD 2749/4885MAPK1 356/4885 |
| US-20020137774-A1 | Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, NRAS | SKP2 334/4885HPGD 3053/4885MAPK1 354/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | SKP2 582/4885HPGD 2745/4885MAPK1 564/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | SKP2 582/4885HPGD 2745/4885MAPK1 564/4885 |
| US-20090227637-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | UBA6, MCM6, UBQLN1 | SKP2 641/4885HPGD 3968/4885MAPK1 3365/4885 |
| US-20030144278-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | SKP2 582/4885HPGD 2745/4885MAPK1 564/4885 |
| US-20110263657-A1 | DIARYL UREAS FOR TREATING HEART FAILURE | UBA6, UBQLN1, UHRF1 | SKP2 1121/4885HPGD 576/4885MAPK1 2589/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | SKP2 1179/4885HPGD 2546/4885MAPK1 391/4885 |
| US-20110158942-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | UBA6, MCM6, UBQLN1 | SKP2 641/4885HPGD 3968/4885MAPK1 3365/4885 |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | SKP2 582/4885HPGD 2745/4885MAPK1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.